<DOC>
	<DOCNO>NCT01195259</DOCNO>
	<brief_summary>Observational analysis data population registeries suggest metformin may associate decreased prevalence malignancy . The ADOPT RECORD study contain group subject randomly allocate metformin rosiglitazone . This meta-analysis combine malignancy serious adverse event ADOPT RECORD order compare incidence metformin rosiglitazone .</brief_summary>
	<brief_title>Malignancy Meta Analysis BRL49653</brief_title>
	<detailed_description>The objective meta-analysis compare incidence malignancy ( exclude non-melanomatous skin cancer ) report serious adverse event ADOPT RECORD study subject randomly allocate treatment metformin allocate rosiglitazone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Subjects ADOPT include metaanalysis ( metformin rosiglitazone group ) dose study medication increase maximum 2g ( metformin ) 8mg ( rosiglitazone ) fast plasma glucose great 140mg/dl . Subjects RECORD include metaanalsyis enter RECORD study take one three sulfonylurea ( glibenclamide , gliclazide glimepiride ) . They randomly allocate metformin rosiglitazone 1:1 ration use addon treatment background sulfonylurea . These subject dose study medication increase maximum 2.55g ( metformin ) 8mg ( rosiglitazone ) HbA1c great 7.0 % .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>ADOPT</keyword>
	<keyword>metformin</keyword>
	<keyword>malignancy</keyword>
	<keyword>RECORD</keyword>
</DOC>